

## 6 Literaturverzeichnis

1. AHN KY, MOHAUPT MG, MADSEN KM et al: In situ hybridization localization of mRNA encoding two inducible nitric oxide synthase in rat kidney. *Am J Physiol* 267: F748-F757 (1994)
2. ALLCOCK GH, HUKKANEN M, POLAK JM et al: Increased nitric oxide synthase-3 expression in kidneys of deoxycorticosterone acetate-salt hypertensive rats. *J Am Soc Nephrol* 10: 2283-2289 (1999)
3. ARDAILLOU R: AngiotensinII receptors. *J Am Soc Nephrol* 11: S30-9 (1999)
4. ASANO N, OGURA T, MIMURA Y et al: Renal AT1 receptor: computerized quantification in spontaneously hypertensive rats and DOCA-salt rats. *Res commun Mol Pathol Pharmacol* 100: 171-180 (1998)
5. BERECEK K, BOHR D: Whole body vascular reactivity during the development of deoxycorticosterone acetate hypertension in the pig. *Circ Res* 42: 764 (1978)
6. BODLIEN A, MÜLLER-ROSENAU A: Orientierende Untersuchungen zum Fürsorgeempfinden und Verantwortungsbewußtsein für Tiere – eine Befragung von Zoobesuchern. Dissertation, Medizinische Hochschule Hannover (1987)
7. di BONA GF: Peripheral and central interactions between the renin-angiotensin system and the renal sympathetic nerves in control of renal function. *Ann N Y Acad Sci* 940: 395-406 (2001)
8. BONNET JM, BOIVIN R, BERNARD N et al: Extrarenal renin-angiotensin systems are unable to maintain blood pressure in sheep. *Clin Exp Pharmacol Physiol* 27(9): 684-9 (2000)
9. BRILLA CG, MATSUBARA LS, WEBER KT: Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. *Am J Cardiol* 71: 12A-16A (1993)
10. BUILD AND BLOOD PRESSURE STUDY. Society of Actuaries. Chicago (1959)
11. BUSCHE S, GALLINAT S, BOHLE RM et al: Expression of angiotensin AT1 and AT2 receptors in adult rat cardiomyocytes after myocardial infarction. *Am J Pathol* 157:605-611 (2000)
12. CHATZIANTONIOU C, PAUTI MD, PINET F et al: Regulation of renin release is impaired after nitric oxide inhibition. *Kidney Int* 49: 626-33 (1996)
13. CHIN SY, WANG CT, MAJID DS et al: Renoprotective effects of nitric oxide in angiotensin II-induced hypertension in the rat. *Am J Physiol* 274: F876-F882 (1998)
14. COLEMAN TG, GUYTON AC: Hypertension caused by salt loading in the dog: III. Onset transients of cardiac output and other circulatory variables. *Circ Res* 25: 152-160 (1963)
15. DAWKINS MS: Die Entdeckung des tierischen Bewußtseins. *Rohwolt Verlag* Reinbek bei Hamburg: S.101ff (1996)
16. DENG X, WELCH WJ, WILCOX CS: Renal vasoconstriction during inhibition of NO synthase: effects of dietary salt. *Kidney Int* 46: 639-646 (1994)
17. EPIDEMIOLOGIE DER HYPERTONIE. Merkblatt der Deutschen Liga zur Bekämpfung des hohen Blutdruckes e. V. Heidelberg. 2. Aufl. (1997)
18. FARO R, TANUS-SANTOS JE, ZAPPELLINI A et al: The role of heart rate in the modulation of the decreased cardiac output induced by acute nitric oxide synthesis inhibition in anaesthetized dogs. *J Auton Pharmacol* 19: 257-262 (1999)
19. FÖLSCH UR, KOCHSIEK K, SCHMIDT RF: Pathophysiologie. *Springer*. Berlin/Heidelberg: S. 134 (2000)
20. FORTEPIANI LA, RODRIGO E, ORTIZ MC et al: Pressure natriuresis in nitric oxide-deficient hypertensive rats. Effect of antihypertensive treatments. *J Am soc Nephrol* 10: 21-27 (1999)

21. FUJIHARA CK, MATTAR AL, VIEIRA JM Jr et al: Evidence for the existence of two distinct functions for the inducible NO Synthase in the rat kidney: effect of aminoguanidine in rats with 5/6 ablation. *J Am Soc Nephrol* 13: 2278-2287 (2002)
22. GÄRTNER K, GEHRKE W et al: Zum subjektiven Empfinden des Menschen gegenüber Tieren – eine orientierende sozialemprirische Befragung von Personen in der Versuchstierforschung. In: *Deutsches Tierärzteblatt*, Nr.9: S. 613f (1983)
23. GALLINAT S, BUSCHE S, RAIZADA MK et al: The angiotensin II type 2 receptor: an enigma with multiple variations. *Am J Physiol Endocrinol Metab* 278: E357-E374 (2000)
24. GANGULI M, TOBIAN L, IWAI J: Cardiac output and peripheral resistance in strains of rats sensitive and resistant to NaCl hypertensnion. *Hypertension* 1: 3-7 (1979)
25. GANTEN, D, RITZ, E: Lehrbuch der Hypertonie. *Schattauer*, Stuttgart (1985)
26. de GASPARO M, CATT KJ, INAGAMI T et al: International Union of Pharmacology. XXIII. The angiotensin II receptors. *Pharmacol Rev* 52: 415-472 (2000)
27. GERNHARDT MM, FLECK C: Der Tierversuch. *Peter Lang Europäischer Verlag der Wissenschaften*. Frankfurt a. M.: S.36 (2000)
28. GOEBELL H, WAGNER J: Innere Medizin. *de Gruyter*. Berlin: S.167 (1992)
29. GOHLKE P, PEES C, UNGER TH: AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. *Hypertension* 81: 349-355 (1998)
30. GREKIN RJ, TERRIS JM, BOHR DF: Electrolyte and hormonal effects of deoxcorticosterone acetate in young pigs. *Hypertension* 2: 326-332 (1980)
31. GROSS V, LIPPOLDT A, SCHNEIDER W et al: Effect of captopril and angiotensin II receptor blockade on pressure natriuresis in transgenic TGR(mRen-2)27 rats. *Hypertension* 26: 471-479 (1995)
32. GROSS V, LIPPOLDT A, BOHLENDER J et al: The renin-angiotensin system and renal function in transgenic (mRen2)27 rats. *Exp Nephrol* 4 [Suppl 1]: 20-26 (1996)
33. GROSS V, LIPPOLDT A, BOHLENDER J et al: Cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice. *J Am Soc Nephrol* 9: 346-354 (1998)
34. GROSS V, SCHUNCK WH, HONECK H et al: Inhibition of pressure natriuresis in mice lacking the AT2 receptor. *Kidney International* 57: 191-202 (2000)
35. GROSS V, WALTHER T, MILIA AF et al: Left ventricular function in mice lacking the AT2 receptor. *J Hypertens* 19: 967-976 (2001)
36. GROSS V, LUFT FC: Exercising restraint in measuring blood pressure in conscious mice. *Hypertension* 41(4): 879-81 (2003)
37. GROSS V, OBST M, KISS E et al: Cardiac hypertrophy and fibrosis in chronic L-NAME treated AT2 receptor deficient mice. *J Hypertens* 22: 1-9 (2004)
38. GUYTON AC, MANNING RD Jr, HALL JE et al: The pathogenic role of the kidney. *J Cardiovasc Pharmacol* 6 Suppl 1: S151-S161 (1984)
39. GUYTON AC: Dominant role of the kidneys and accessory role of whole-body autoregulation in the pathogenesis of hypertension. *Am J Hypertens* 2: 575-585 (1989)
40. GUYTON AC: Abnormal renal function and autoregulation in essential hypertension. *Hypertension* 18: III49-III53 (1991)

41. GUYTON AC: Kidneys and fluids in pressure regulation. Small volume but large pressure changes. *Hypertension* 19: 12-18 (1992)
42. HABLY C, VAG J, BARTHA J: Nitric oxide synthase inhibition increases vascular resistance in sodium and water loaded rats. *Res Exp Med (Berl)* 198: 145-156 (1998)
43. HALL CE, HALL O: Interaction between desoxycorticosterone treatment, fluid intake, sodium consumption, blood pressure, and organ changes in rats drinking water, saline, or sucrose solution. *Can J Physiol Pharmacol* 47: 81 (1969)
44. HARA K, KOBAYASHI N, WATANABE S et al : Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats. *Am J Hypertens* 14: 321-330 (2001)
45. HARRIS PJ, NAVAR LG: Tubular transport responses to angiotensin. *Am J Physiol* 248: F621-F630 (1985)
46. HEIN L, BARSCH GS, PRATT RE et al: Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. *Nature* 377: 744-747 (1995)
47. HINOJOSA-LABORDE C, GREENE AS, COWLEY AW Jr: Autoregulation of the systemic circulation in conscious rats. *Hypertension* 11: 685-691 (1988)
48. HÖFFE, O: Der wissenschaftliche Tierversuch: bioethische Überlegungen. In: *Schweizerische Ärztezeitung*, 63/18: S.1004 (1982)
49. HOFKER, M H, van DEURSEN, J (Hrsg.): Transgenic Mouse – Methods and Protocols. Methods in Molecular Biology. Volume 209. *Humana Press*. Totowa: S.3 (2003)
50. HORIUCHI M, AKISHITA M, DZAU VJ: Recent progress in angiotensin II type receptor research in the cardiovascular system. *Hypertension* 33: 613-621 (1999)
51. HORIUCHI M, HAYASHIDA W, AKISHITA M et al: Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. *Circ Res* 84: 876-882 (1999)
52. HU CT, CHANG KC, WU CY et al: Acute effects of nitric oxide blockade with L-NAME on arterial hemodynamics in the rat. *Br J Pharmacol* 19: 257-262 (1999)
53. HUANG M, MANNING RD JR, LEBLANC MH et al: Overall hemodynamic studies after the chronic inhibition of endothelial derived nitric oxide in rats. *Am J Hypertens* 8: 358-364 (1995)
54. ICHIHARA S, SENBONMATSU T, PRICE E Jr et al: Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. *Circulation* 104: 346-351 (2001)
55. ICHIKI T, LABOSKY PA, SHIOTA C, OKUYAMA S et al: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II-type2 receptor. *Nature* 377: 748-750 (1995)
56. INAGAMI T, SENBONMATSU T: Dual effects of angiotensin II type 2 receptor on cardiovascular hypertrophy. *Trends Cardiovasc Med*. 11: 324-328 (2001)
57. ITO A, EGASHIRA K, KADOKAMI T et al : Chronic inhibition of endothelium-derived nitric oxide synthesis causes coronary microvascular structural changes and hyperreactivity to serotonin in pigs. *Circulation* 92: 2636-2644 (1995)
58. JANSSEN BJ, SMITS JF: Autonomic control of blood pressure in mice: basic physiology and effects of genetic modification. *Am J Physiol Regul Integr Comp Physiol* 282: R1545-R1564 (2002)
59. JOHNSON MD, MALVIN RL: Stimulation of renal sodium reabsorption by angiotensin II. *Am J Physiol* 232: F298-F306 (1977)

60. JOVER B, HERIZI A, VENTRE F et al: Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. *Hypertension* 21: 944-948 (1993)
61. KADOKAMI T, EGASHIRA K, KUWATA K et al: Altered serotonin receptor subtypes mediate coronary microvascular hyperreactivity in pigs with chronic inhibition of nitric oxide synthesis. *Circulation* 94: 182-189 (1996)
62. KANT I: Die Metaphysik der Sitten. *Reclam Stuttgart*: S. 329f (1990)
63. KATOH M, EGASHIRA K, USUI M et al: Cardiac angiotensin II type 2 receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. *Circ Res* 83: 743-751 (1998)
64. KATHOLI RE, NAFTILAN AJ, OPARIL S: Importance of renal sympathetic tone in the development of DOCA-salt hypertension in the rat. *Hypertension* 2: 266-273 (1980)
65. KEIL U, STIEBER J, DÖRING A, FRICKE H: Ergebnisse der Münchner Blutdruck-Studie und Aufbau des Münchner Blutdruckprogrammes. *Das öffentl. Gesundheitswesen* 44:727-732 (1982)
66. KESTELOOT H, PARK BC, LEE CS, BREMS-HEYNS E et al.: A comparative study of blood pressure and sodium intake in Belgium and Korea. *Europ J Cardiol* 11: 169-182 (1980)
67. KEYS A, ARAVANIS CH, BLACKBURN H, van BUCHEN FSP, BUZINA R et al: Epidemiological studies related to coronary heart disease: Characteristics of men aged 40-59 in seven countries. *Acta med scand.* Suppl. 460 (1966)
68. KIM S, OHTA K, HAMAGUCHI A et al: Role of angiotensin II in renal injury of deoxcorticosterone acetate-salt hypertensive rats. *Hypertension* 24: 195-204 (1994)
69. KING AJ, MERCER P, TROY JL et al: Endothelium-derived relaxing factor and the vascular reply to systemic hypertension. *J Am Soc Nephrol* 2: 1072-1077 (1991)
70. KONE BC, BAYLIS C: Biosynthesis and homeostatic role of nitric oxide in the normal kidney. *Am J Physiol* 272: F561-F578 (1997)
71. KONE BC, HIGHAM S: Nitric oxide inhibits transcription of the Na<sup>+</sup>-K<sup>+</sup>-ATPase alpha1-subunit gene in an MTAL cell line. *Am J Physiol* 276: F614-F621 (1999)
72. KURISU S, OZONO R, OSHIMA T et al: Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. *Hypertension* 41: 99-107 (2003)
73. LEE K, KIM S, JUNG M et al: Altered expression of vascular natriuretic peptide receptors in experimental hypertensive rats. *Clin Exp Pharmacol Physiol* 29: 299-303 (2002)
74. LI JS, TOUYZ RM, SCHRIFIN EL : Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats. *Hypertension* 31: 487-492 (1998)
75. LIPPOLDT A, GROSS V, SCHNEIDER K et al: Nitric oxide synthase and renin-angiotensin system gene expression in salt-sensitive and salt resistant Sabra rats. *Hypertension* 30: 409-415 (1997)
76. LIU R, PERSSON AE: AngiotensinII stimulates calcium and nitric oxide release from macula densa cells through AT1 receptors. *Hypertension* 26 (2004)
77. LO M, LIU KL, LANTELME P et al: Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. *J Clin Invest* 95: 1349-1397 (1995)
78. LUCIUS R, GALLINAT S, ROSENSTIEL P et al: The angiotensin II type 2 receptorpromotes axonal regeneration in the optic nerve of adult rats. *J Exp Med* 4: 661-670 (1998)
79. MADRID MI, GARCIA-SALOM M, TORNEL J et al: Effect of interaction between nitric oxide and angiotensin II on pressure diuresis and natriuresis. *Am J Physiol* 273: R1676-R1682 (1997)

80. MAJID DS, SAID KE, OMORO SA et al: Nitric oxide dependency of arterial pressure-induced changes in renal interstitial hydrostatic pressure in dogs. *Circ Res* 88: 347-351 (2001)
81. MANNING RD Jr, COLEMANN TG, GUYTON AC et al: Essential role of mean circulatory filling pressure in salt-induced hypertension. *Am J Physiol* 236: R40-R47 (1979)
82. MANSOUR SL, THOMAS KR, CAPECCHI MR: Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non selectable genes. *Nature* 336, 348-352 (1988)
83. van der MARK J, KLINE RL: Altered pressure natriuresis in chronic angiotensin II hypertension in rats. *Am J Physiol* 266: R739-R748 (1994)
84. MATTSON DL, RAFF H, ROMAN RJ: Influence of angiotensin II on pressure natriuresis and renal hemodynamics in volume expanded rats. *Am J Physiol* 260: R1200-R1209 (1991)
85. MATTSON DL, ROMAN RJ, COWLEY AWJ: Role of nitric oxide in renal papillary blood flow and sodium excretion. *Hypertension* 19: 766-769 (1992)
86. MERVAALA E, DEHMEL B, GROSS V et al: Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensin genes. *J Am Soc Nephrol* 10: 1669-1680 (1999)
87. MILLER AW, BOHR DF, SCHORK AM et al: Hemodynamic responses to DOCA in young pigs. *Hypertension* 1: 591-597 (1979)
88. MOHAUPT MG, ELZIE JL, AHN KY et al: Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. *Kidney Int* 46: 653-665 (1994)
89. MONTANI JP, MIZELLE HL, ADAIR TH et al: Regulation of cardiac output during aldosterone-induced hypertension. *J Hypertens Suppl* 7: S206-S207 (1989)
90. NADAUD S, MAO C, LUVARA G et al: Isoform-specific regulation of nitric oxide synthase mRNA in the kidney by sodium and blood pressure. *J Hypertens* 16: 1315-1323 (1998)
91. NAITOH M, SUZUKI H, ARAKAWA K et al: Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low renin hypertension. *Am J Physiol* 272: H679-H687 (1997)
92. NAKANISHI K, MATTSON DL, COWLEY AWJ: Role of renal medullary blood flow in the development of L-NAME hypertension in rats. *Am J Physiol* 268: R317-R323 (1995)
93. NAVAR LG, ROSIVALL L: Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics. *Kidney Int* 25: 857-868 (1984)
94. NUMAGUCHI K, EGASHIRA K, TAKEMOTO M et al: Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. *Hypertension* 26: 957-962 (1995)
95. OBST M, GROSS V, JANKE J et al: Pressure natriuresis in AT2 receptor-deficient mice with L-NAME hypertension. *J Am Soc Nephrol* 14: 303-310 (2003)
96. OBST M, GROSS V, BONARTSEV A et al: Nitric oxide synthase expression in AT2 receptor-deficient mice after DOCA-salt. *Kidney Int* 65(6): 2268-78 (2004)
97. PEOTTA VA, VASQUEZ EC, MEYRELLES SS: Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. *Hypertension* 38 : 555-559 (2001)
98. PIEPER U, THURNHERR U (Hrsg.): Angewandte Ethik, Eine Einführung, Beck'sche Reihe 1261, Verlag C.H. Beck. München: S.66 (1998)
99. POLLOCK DM, POLAKOWSKI JS, DIVISH BJ et al: Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. *Hypertension* 21: 660-666 (1993)

100. POLLOCK DM, DEREBAIL VK, YAMAMOTO T et al: Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats. *Gen Pharmacol* 34: 337-342 (2000)
101. PRECHTL P, BURKARD FP (Hrsg.): Metzler Philosophie Lexikon. *Metzler Verlag* 2. Aufl.: S. 351 (1999)
102. RIBEIRO MO, ANTUNES E, de NUCCI G et al: Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. *Hypertension* 20: 298-303 (1992)
103. ROSSI MA, RAMOS SG, PRADO CM: Chronic inhibition of nitric oxide synthase induces hypertension and cardiomyocyte mitochondrial and myocardial collagen remodeling in the absence of hypertrophy. *J Hypertens* 21: 993-1001 (2003)
104. RUSSEL WMS, BURCH RL: The principles of human experimental technique. *Methuen*, London (1959)
105. SAAVEDRA JM, HAUSER W, CIUFFO G et al: Increased AT1 receptor expression and mRNA in kidney glomeruli of AT2 receptor gene-disrupted mice. *Am J Physiol Renal Physiol* 280: F71-F78 (2001)
106. SADOSHIMA J: Cytokine actions of angiotensin II. *Circ Res* 86: 1187-1189 (2000)
107. SCHMIDT RF, THEWS G, LANG F (Hrsg.): Physiologie des Menschen. *Springer-Verlag*. Berlin-Heidelberg-New York (2000)
108. SCHNACKENBERG C, PATEL AR, KIRCHNER KA et al: Nitric oxide, the kidney and hypertension. *Clin Exp Physiol* 24: 600-606 (1997)
109. SCHWEITZER A: Die Ehrfurcht vor dem Leben, Grundtexte aus fünf Jahrzehnten. *Verlag C. H. Beck* München 6. Aufl.: S.92 (1991)
110. SCHWOBEL J, FISCHER T, LANZ B et al: Angiotensin II receptor subtypes determine induced NO production in rat glomerular mesangial cells. *Am J Physiol Renal Physiol* 279: F1092-F1100 (2000)
111. SENBONMATSU T, ICHIHARA S, PRICE E Jr et al: Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. *J Clin Invest.* 106: R25-R29 (2000)
112. SHULTZ PJ, TOLINS JP: Adaptation to increased dietary salt intake in the rat. Role of endogenous nitric oxide. *J Clin Invest* 91: 642-650 (1993)
113. SIGMON DH, BEIERWALTES WH: Angiotensin II: Nitric oxide interaction and the distribution of blood flow. *Am J Physiol* 265: R1276-R1283 (1993)
114. SIRAGI HM, JAFFA AA, MARGOLIUS HS et al: Renin-angiotensin system modulates renal bradykinin production. *Am J Physiol* 271: R1090-R1095 (1996)
115. SIRAGI HM, CAREY RM: Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. *Hypertension* 33: 1237-1242 (1999)
116. SIRAGI HM, INAGAMI T, ICHIKI T et al: Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. *Proc Natl Acad Sci USA* 96: 6505-6510 (1999)
117. SUGA H, SAGAWA K, SHOUKAS AA: Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. *Circ Res* 32: 314-322 (1973)
118. SUGA H, SAGAWA K: Instantaneous pressure volume relationship and their ratio in the excised, supported canine left ventricle. *Circ Res* 35: 117-126 (1974)
119. SZENTIVANYI MJ, MAEDA CY, COWLEY AWJ: Local renal medullary L-NAME infusion enhances the effect of long-term angiotensin II treatment. *Hypertension* 33: 440-445 (1999)

120. TAKEMOTO M, EGASHIRA K, TOMITA H et al: Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. *Hypertension* 30: 1621-1627 (1997)
121. TAN DY, MENG S, CASON GW et al: Mechanisms of salt-sensitive hypertension: Role of inducible nitric oxide synthase. *Am J Physiol Regul Integr Comp Physiol* 279: R2297-R2303 (2000)
122. TANAKA M, TSUCHIDA S, IMAI T et al: Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 knockout mice. *Biochem Biophys Res Commun* 258: 194-198 (1999)
123. TIAN B, LIU J, BITTERMAN P et al: Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB. *Am J Heart Circ Physiol* 285: H1105-H1112 (2003)
124. TIERSCHUTZBERICHT: „Bericht über den Stand der Entwicklung des Tierschutzes“, Unterrichtung durch die Bundesregierung, *Bonner Universitäts-Buchdruckerei* (1991-99)
125. TSUTSUMI Y, MATSUBARA H, MASAKI H et al: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. *J Clin Invest* 104: 925-935 (1999)
126. USUI M, ICHIKI T, KATOH M et al: Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. *Hypertension* 32: 527-533 (1998)
127. VARAGIC J, JERKIC M, JOVOVIC D et al: Regional hemodynamics after chronic nitric oxide inhibition in spontaneously hypertensive rats. *Am J Med Sci* 320: 171-176 (2000)
128. VERVOORT VS, BEACHEM MA, EDWARDS PS: AGTR2 mutations in x-linked mental retardation. *Science* 296: 2401-2403 (2002)
129. YAMAMOTO S, HAYASHI N, KOMETANI M et al: Pharmacological profile of valsartan, a non-peptide angiotensin I type 1 receptor antagonist. 1st communication: Antihypertensive effects of valsartan in hypertensive models. *Arzneimittelforschung* 47: 604-612 (1997)
130. YANG Y, MACDONALD GJ, DUGGAN KA: A study of angiotensin receptor expression by nitric oxide in rat adrenal glands. *Hypertension* 32: 527-533 (1998)
131. YOUNG M, FULLERTON M, DILLEY R et al: Mineralcorticoids, hypertension, and cardiac fibrosis. *J Clin Invest* 93: 2578-2583 (1994)
132. YU M, GOPALAKRISHNAN V, WILSON T et al: Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension. *Am J Physiol Heart Circ Physiol* 281: H2511-H2517 (2001)
133. ZIMMERMAN BG, RAICH PC: Renal hemodynamics in canine DOCA-salt hypertension: Effect of calcium channel blockade. *Tohoku J Exp Med* 166: 147-154 (1992)
134. ZOU AP, WU F, COWLEY AW Jr: Protective effect of angiotensin II-induced increase in nitric oxide in the renal medullary circulation. *Hypertension* 31: 271-276 (1998)
135. ZOU AP, COWLEY AW Jr: Role of nitric oxide in the control of renal function and salt sensitivity. *Curr Hypertens Rep* 1:178-186 (1999)